05:42 PM EST, 01/09/2025 (MT Newswires) -- Mural Oncology ( MURA ) said Thursday it achieved 75% of the required overall survival events for the planned interim analysis in its ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab for platinum-resistant ovarian cancer.

The company said it extended its cash runway projection into Q1 2026.

Mural also expanded its pipeline in Q4 2024 by nominating two new development candidates for its interleukin-18 and interleukin-12 programs, it added.

The company said it anticipates filing an Investigational New Drug application or Clinical Trial Application for a phase 1 trial of MURA-8518 in Q4 2025.